Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell

NCT02478502 is registered in ClinicalTrials.gov with University Hospital, Akershus as lead sponsor.

NCT NCT02478502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02478502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Lead sponsor
University Hospital, Akershus
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2015
Completion date
December 31, 2022
Enrollment
14 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

testicular cancer